Director David C. Greenberg recently conducted several transactions involving common stock of ICU Medical Inc., which trades under the NASDAQ ticker ICUI. These movements, reported on May 12 and May 13, 2026, included both the disposition of shares and the acquisition through structured vesting and option exercises.
On May 12, Mr. Greenberg sold a total of 2,424 shares of common stock. The selling price for these shares was set at $122.91 per share, resulting in a total proceeds value of $297,933. It is noted that all the disposed shares were executed at this precise rate.
The acquisition side of his activity shows multiple components. Prior to the sale on May 12, Mr. Greenberg increased his holdings by acquiring 2,424 shares through the exercise of non-qualified stock options. The cost basis for these exercised options was $101.06 per share. Following this, on May 13, he acquired an additional 1,254 common shares resulting from the vesting of restricted stock units (RSUs). These particular RSUs do not require a purchase or exercise price and are scheduled to vest either on the anniversary date of their grant or during the subsequent annual stockholder meeting. The combined value associated with these initial exercises and vestings spanned a range, calculated between $0.0 and $101.06 per share, amounting to approximately $244,969.
Further activity was reported on May 13 when Mr. Greenberg received an additional grant of 1,475 restricted stock units. Like the previous batch, these awards carry no purchase or exercise price and are subject to vesting on the anniversary date of their grant or at the following annual stockholder meeting.
Following the entirety of these reported transactions, Mr. Greenberg's direct holding in ICU Medical common stock totals 9,214 shares.
Recent Corporate Performance Context
In separate but relevant company news, ICU Medical Inc. released its first-quarter earnings for 2026. The financial results demonstrated a notable performance relative to market predictions. Specifically, the company reported Earnings Per Share (EPS) of $1.97. This figure exceeded the forecasted estimate of $1.76, representing an 11.93% positive surprise.
Beyond earnings, quarterly revenue reached $526 million. This total slightly surpassed the anticipated revenue of $522.38 million. These figures collectively underscore a robust and strong commencement to the year for ICU Medical. The market responded positively to this earnings announcement. While no updates were provided concerning potential mergers or acquisitions, the company’s quarterly earnings performance remains a key area of focus for investors monitoring its overall financial health.
Investment Considerations
From an analytical perspective, while the stock currently trades at $122.04, this represents a decline of 14% year-to-date. Despite this downward movement, analyses provided by InvestingPro suggest that the shares may still be undervalued when measured against the company's calculated Fair Value. The general market performance data indicates the stock closed at $122.04, showing a minor change of 0.00% after hours.
Risks
- The stock has seen a substantial decline of 14% year-to-date, which represents a notable market risk factor.
- Future valuation depends heavily on continued strong earnings performance and the ability to meet stakeholder expectations following the positive Q1 report.
- No updates were provided regarding potential mergers or acquisitions, leaving the strategic growth trajectory subject to future announcements.
More from Insider Trading
Risks
- The stock has seen a substantial decline of 14% year-to-date, which represents a notable market risk factor.
- Future valuation depends heavily on continued strong earnings performance and the ability to meet stakeholder expectations following the positive Q1 report.
- No updates were provided regarding potential mergers or acquisitions, leaving the strategic growth trajectory subject to future announcements.